Afficher la notice abrégée

Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196

dc.rights.licenseopenen_US
dc.contributor.authorDE WIT, Stephane
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorBONNET, Fabrice
dc.contributor.authorOSIYEMI, Olayemi
dc.contributor.authorBISSHOP, Fiona
dc.contributor.authorOLALLA, Julian
dc.contributor.authorROUTY, Jean-Pierre
dc.contributor.authorWYEN, Christoph
dc.contributor.authorMOODLEY, Riya
dc.contributor.authorPAPPA, Keith
dc.contributor.authorWANG, Ruolan
dc.contributor.authorOYEE, James
dc.contributor.authorSAGGU, Parminder
dc.contributor.authorLETANG, Emilio
dc.contributor.authorWYNNE, Brian
dc.contributor.authorJONES, Bryn
dc.contributor.authorSMITH, Kimberly Y
dc.contributor.authorAIT-KHALED, Mounir
dc.date.accessioned2024-05-02T11:13:24Z
dc.date.available2024-05-02T11:13:24Z
dc.date.issued2024-03-01
dc.identifier.issn1944-7884en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/199572
dc.description.abstractEnBACKGROUND: Switching to the 2-drug regimen dolutegravir/lamivudine demonstrated durable non-inferior efficacy vs continuing 3- or 4-drug tenofovir alafenamide-based regimens for maintaining virologic suppression in people with HIV-1 through Week 144 in TANGO. SETTING: 134 centers, 10 countries. METHODS: Adults with HIV-1 RNA <50 copies/mL for >6 months and no history of virologic failure were randomized to switch from stable tenofovir alafenamide-based regimens to dolutegravir/lamivudine on Day 1 (early-switch group) for 196 weeks. Those randomized to continue tenofovir alafenamide-based regimens on Day 1 who maintained virologic suppression at Week 144 switched to dolutegravir/lamivudine at Week 148 (late-switch group). Efficacy, safety, and tolerability (including weight and biomarker changes) of dolutegravir/lamivudine in early-switch and late-switch groups were assessed through Week 196. RESULTS: Overall, 369 participants switched to dolutegravir/lamivudine on Day 1 (early-switch) and 298 switched at Week 148 (late-switch). In the early-switch group, 83% (306/369) maintained virologic suppression through Year 4, and 3% (11/369) reported new adverse events between Weeks 144 and 196. The late-switch group at Week 196 and early-switch group at Week 48 had comparable proportions with virologic suppression (93% each) and similar safety profiles. No late-switch participants and 1 early-switch participant met confirmed virologic withdrawal criteria through Week 196, with no resistance-associated mutations observed. Treatment continued to be well tolerated long-term. CONCLUSION: Switching from tenofovir alafenamide-based regimens to dolutegravir/lamivudine showed durable efficacy, high barrier to resistance, and good tolerability through 4 years. These results support dolutegravir/lamivudine as a robust treatment for maintaining virologic suppression.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enAntiretroviral therapy
dc.subject.en2-drug regimen
dc.subject.enIntegrase strand transfer inhibitor
dc.title.enDurable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196
dc.title.alternativeJ Acquir Immune Defic Syndren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1097/QAI.0000000000003395en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed38346427en_US
bordeaux.journalJournal of Acquired Immune Deficiency Syndromes - JAIDSen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamGHIGS_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDInstitut de Recherche pour le Développementen_US
bordeaux.identifier.funderIDViiV Healthcareen_US
hal.identifierhal-04566132
hal.version1
hal.date.transferred2024-05-02T11:13:28Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Journal%20of%20Acquired%20Immune%20Deficiency%20Syndromes%20-%20JAIDS&amp;rft.date=2024-03-01&amp;rft.eissn=1944-7884&amp;rft.issn=1944-7884&amp;rft.au=DE%20WIT,%20Stephane&amp;BONNET,%20Fabrice&amp;OSIYEMI,%20Olayemi&amp;BISSHOP,%20Fiona&amp;OLALLA,%20Julian&amp;rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_JAcquirImmuneDeficSyndr_20 ...
Taille:
646.8Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
811octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée